title: [The administration of tobramycin in the 2nd and 3rd trimester of pregnancy: contribution to a pharmacokinetic study for the adaptation of posology].
abstract: Aminoglycosides are currently used during pregnancy for the treatment of Staphylococcus, Enterobacteriaceae, Listeria monocytogenes, and Pseudomonas aeruginosa infections. The pharmacokinetics of tobramycin, an aminoglycoside antibiotic, was investigated after a 2.5 mg/kg short intravenous infusion and a once-daily dose regime in 18 pregnant women divided into 2 groups of 9 during the second (Group I: from 20 to 28 weeks of amenorrhoea) and the third (Group II: greater than or equal to 28 weeks of amenorrhoea) trimesters of pregnancy (during these period, risks of infectious diseases are increased). Plasma concentrations of tobramycin were measured by fluorescence polarization immunoassay (FPIA). The decrease of clearance (decrement of 27.6%), at 28 weeks and more gestation leads to an increase in the half-life and the MRT observed in the second group (increment of 49% and 41% respectively), whereas the volume of distribution remained unchanged in the two groups. No accumulation of the drug was observed in pregnant women. Pharmacokinetic disorders are correlated with the duration and moreover with the weight deviation of the women i.e., the growth of the conceptus. In 10 cases, a feto-maternal concentration ratio was calculated at delivery using an umbilical cord blood sample. This findings suggest a phenomenon of accumulation in the conceptus. To limit the potential nephrotoxicity and ototoxicity of tobramycin for the mother and the fetus, a once-daily dose regime seems to be an advanced solution for treatment of nonneutropenic pregnant women.
authors.affiliation: Service de Gynécologie-Obstétrique, Hôpital Antoine-Béclère, Clamart.
authors.forename: H
authors.initials: H
authors.lastname: Fernandez
authors.forename: P
authors.initials: P
authors.lastname: Bourget
authors.forename: C
authors.initials: C
authors.lastname: Delouis
authors.forename: S
authors.initials: S
authors.lastname: Demirdjian
mesh_terms: D000042:Absorption; D000328:Adult; D001682:Biological Availability; D005260:Female; D005865:Gestational Age; D006801:Humans; D007262:Infusions, Intravenous; D008431:Maternal-Fetal Exchange; D011247:Pregnancy / Q000097:blood / Q000378:metabolism* / Q000652:urine; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D013997:Time Factors; D014018:Tissue Distribution; D014031:Tobramycin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
chemical_list: D014031:Tobramycin